Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01575873 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 795
- Enrollment target
NCT01575873: Completed Phase 3 study, sponsored by Amgen.
NCT01575873 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 795 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01575873, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 795 participants
- Enrollment target
Study Summary
This is a 2-year study to evaluate the effect of denosumab versus risedronate in adults with glucocorticoid-induced osteoporosis.
Primary Outcome
Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA).
Interventions
- DRUG Denosumab
- DRUG Placebo for risendronate
- DRUG Risendronate
- DRUG Placebo for denosumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 795 participants |
| Start Date | 2012-03-28 |
| Est. Completion | 2017-06-29 |
| Phase | Phase 3 |
What the finished NCT01575873 record still lists
NCT01575873 is an interventional study that assigns participants to a tested intervention. The registered 795 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Denosumab is the first listed.
NCT01575873 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01575873 about?
NCT01575873 is a clinical study titled "Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids". This is a 2-year study to evaluate the effect of denosumab versus risedronate in adults with glucocorticoid-induced osteoporosis.
What is the current status of trial NCT01575873?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 795 participants. The study started on 2012-03-28. Estimated completion is 2017-06-29.
What interventions are being tested in trial NCT01575873?
The interventions under investigation include: Denosumab (DRUG), Placebo for risendronate (DRUG), Risendronate (DRUG), Placebo for denosumab (DRUG).
Who is sponsoring clinical trial NCT01575873?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01575873's enrollment target sits among peer trials
795 428th of 2000 higher than 1,572 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06208150 · 795 participants · Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- NCT06724172 · 795 participants · NA
CHIME: Comparing Health Interventions for Maternal Equity
- NCT05150691 · 796 participants · Phase 1
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- NCT06051058 · 798 participants · NA
Care Transitions App for Patients With Multiple Chronic Conditions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI